LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Khalili, H.; Khaw, P. T.; Brocchini, S. (2016)
Publisher: Royal Society of Chemistry
Languages: English
Types: Article
Subjects:

Classified by OpenAIRE into

mesheuropmc: stomatognathic system
The Fc-fusion mimetic RpR 2[combining low line] was prepared by disulfide bridging conjugation using PEG in the place of the Fc. RpR 2[combining low line] displayed higher affinity for VEGF than aflibercept. This is caused primarily by a slower dissociation rate, which can prolong a drug at its site of action. RpRs have considerable potential for development as stable, organ specific therapeutics.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Heidelberger, I. Teo, M. Zloh, and S. Brocchini, Nat. Chem. Biol., 2006, 2, 312-313; (b) S. Balan, J. W. Choi , A. Godwin, I. Teo, C. M. Laborde, S. Heidelberger, M. Zloh, S. Shaunak, and S. Brocchini, Bioconjugate Chem., 2007, 18, 61-76.
    • G. Badescu, P. Bryant, M. Bird, K. Henseleit, J. Swierkosz, V. Parekh, R. Tommasi, E. Pawlisz, K. Jurlewicz, M. Farys, N. Camper, X. Sheng, M. Fisher, R. Grygorash, A. Kyle, A. Abhilash, M. Frigerio, J. Edwards, and A. Godwin, Bioconjugate Chem., 2014, 25, 1124-1136.
    • H. Khalili, A. Godwin, J. W. Choi, R. Lever, P. T. Khaw, and S. Brocchini, Bioconjugate Chem., 2013, 24, 1870-1882.
    • Somavarapu, J. Liddell, K. Powell, M. Zloh, J.-W. Choi, A. Godwin, and S. Brocchini, Bioconjugate Chem, 2012, 23, 248-263.
    • H. Khalili, A. Godwin, J. W. Choi, R. Lever, P. T. Khaw, and S. Brocchini, Bioconjugate Chem., 2013, 24, 1870-1882.
    • (a) S. M. Chamow, T. Ryll, H. B. Lowman, and D. Farson, eds. Therapeutic Fc-Fusion Proteins. Vol. 10. 2013, Wiley Blackwell: Weinheim. 419; (b) D. M. Czajkowsky, J. Hu, Z.
    • Shao, and R. J. Pleass, EMBO Mol. Med., 2012, 4, 1015- 1028.
    • W. R. Strohl, BioDrugs 2015, 29, 215-239.
    • (a) A. B. V. Spriel, H. H. V. Ojik, and J. G. J. Winkel, Immunol. Today 2000, 21, 391-398; (b) H. R.
    • Hoogenboom, Nat. Biotechnol., 1997, 15, 125-126.
    • Randolph, J. Pharm. Sci., 2012, 101, 1400-1409; (b) M. C.
    • S. Katayama, Pharm. Res., 2010, 27, 544-575.
    • Aalberse, and P. Parren, Science 2007, 13, 1554-1557; (b) S. Murinello, R. F. Mullins, A. J. Lotery, V. H. Perry, and J.
    • L. Teeling, Invest. Ophthalmol. Vis. Sci., 2014, 55, 247-258; (c) A. L. Nelson, MAbs, 2010, 2, 77-83; (d) A. Chapman, P.
    • Antoniw, M. Spitali, S. West, S. Stephens, and D. King, Nat. Biotechnol., 1999, 17, 780-783.
    • (a) EMA (European Medicines Agency), Assessment report for aflibercept (EMA/646256/2012), European Medicines Agency Committee for Medicinal Products for Human Use, Editor. 2012. p. 83; (b) K. K. Ciombor, J. Berlin, and E.
    • Chan, Clin. Cancer. Res., 2013, 19, 1920-1925; (c) J.
    • Acad. Sci. U S A, 2002, 99, 11393-11398.
    • Brocchini, Nat. Chem. Biol., 2006, 2, 312-313; (b) S. Balan, J. W. Choi , A. Godwin, I. Teo, C. M. Laborde, S.
    • Heidelberger, M. Zloh, S. Shaunak, and S. Brocchini, Bioconjugate Chem., 2007, 18, 61-76.
    • Brocchini, and A. Godwin, Bioconjugate Chem., 2014, 25, 460-469.
    • H. Khalili, A. Godwin, J. Choi, R. Lever, and S. Brocchini, Bioconjugate Chem., 2012, 23, 2262-2277.
    • (a) M. G. Mage, Methods Enzymol., 1980, 70, 142-150; (b) P. Parham, J. Immunol., 1983, 131, 2895-2902.
    • (a) B. P. Johansson, O. Shannon, and L. Bjorck, PLoS One, 2008, 3, 1-6; (b) P. Ã…kesson, L. Moritz, M. Truedsson, B.
    • Christensson, and U. V. Pawel-Rammingen, Infection and Immunity 2006, 74, 497-503.
    • C. Fee, Biotechnol. Bioeng., 2007, 98, 725-731.
    • (a) F. Lo Verso and C. N. Likos, Polymer, 2008, 49, 1425- 1434; (b) A. N. Semenov, J. F. Joanny, and A. R. Khokhlov, Macromolecules, 1995, 28, 1066-1075.
    • Ferrara, and S. Yadav, Mol. Pharm., 2014, 11, 3421-3430.
    • G. Vauquelin and S. J. Charlton, Br. J. Pharmacol., 2010, 161, 488-508.
    • (a) W. Paul, ed. Fundamental immunology. 2012, Lippincott Williams and Wilkins. . 140-142; (b) L. J. Harris, S. B. Larson, E. Skaletsky, and A. Mcpherson, Immunol.
    • Rev. , 1998, 163, 35-43; (c) X. Wang, S. Kumar, and S.
    • Singh, Pharm. Res., 2011, 28, 3128-3143.
    • (a) J. Vlasak and R. Ionescu, MAbs, 2011, 3, 253-263; (b) B.
    • Biol. Chem., 2012, 287, 5891-5897.
    • Y. Wang, D. Fei, M. Vanderlaan, and A. Song, Angiogenesis, 2004, 7, 335-345
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article